Optimizing Strategy of Coronary Revascularization in Patients With Multivessel Lesions Combined Heart Failure (OSCRM-HF)
Heart Failure Due to Coronary Artery Disease
About this trial
This is an interventional treatment trial for Heart Failure Due to Coronary Artery Disease focused on measuring heart failure, coronary artery disease, biomarkers, Percutaneous Coronary Intervention, PCI, Coronary Artery Bypass Grafting, CABG
Eligibility Criteria
Inclusion Criteria:
- Age ≥18 years
- with at least 2 lesion vessels defined as ≥50% narrowing of the luminal diameter as shown by coronary angiography, including LAD
- LVEF≤50% as shown in echocardiography
Exclusion Criteria:
- with other severe diseases combined and will be alive for less than 12 months
- combining valvular heart disease
- pregnant or lactating women
- during the acute phase of ST-elevation acute myocardial infarction
- with severe renal dysfunction requiring dialysis to cure
- hard to participate in the investigation or accept the follow-up visits
- those who have already taken PCI treatment before
- with other diseases which need to be treated by surgery
Sites / Locations
- Ruijin Hospital, Shanghai Jiaotong University School of MedicineRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Coronary Artery Bypass Grafting
Percutaneous Coronary Intervention
Hybrid Coronary Revascularization
Using coronary artery bypass grafting surgery as the coronary revascularization therapy for patients enrolled.
Using percutaneous coronary intervention as the coronary revascularization therapy for patients enrolled.
Patients enrolled will take coronary artery bypass grafting surgery at first, then treated with percutaneous coronary intervention.